prikaz prve stranice dokumenta Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab
  Download
PDF 235.58 KB
Scientific paper - Case study
Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab
Acta clinica Croatica, 62 (2023), 2; 382-385. https://doi.org/10.20471/acc.2023.62.02.19
Krečak, Ivan; Gverić-Krečak, Velka

Cite this document

Krečak, I. & Gverić Krečak, V. (2023). Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab. Acta clinica Croatica, 62. (2), 382-385. doi: 10.20471/acc.2023.62.02.19

Krečak, Ivan and Velka Gverić Krečak. "Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab." Acta clinica Croatica, vol. 62, no. 2, 2023, pp. 382-385. https://doi.org/10.20471/acc.2023.62.02.19

Krečak, Ivan and Velka Gverić Krečak. "Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab." Acta clinica Croatica 62, no. 2 (2023): 382-385. https://doi.org/10.20471/acc.2023.62.02.19

Krečak, I. and Gverić Krečak, V. (2023) 'Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab', Acta clinica Croatica, 62(2), pp. 382-385. doi: 10.20471/acc.2023.62.02.19

Krečak I, Gverić Krečak V. Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab. Acta clinica Croatica [Internet]. 2023 [cited 2024 July 07];62(2):382-385. doi: 10.20471/acc.2023.62.02.19

I. Krečak and V. Gverić Krečak, "Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab", Acta clinica Croatica, vol. 62, no. 2, pp. 382-385, 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:287378. [Accessed: 07 July 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab
Title (croatian)Refraktorni Guillain-Barreov sindrom u bolesnika s asimptomatskim multiplim mijelomom uspješno liječenim niskom dozom rituksimaba
AuthorIvan Krečak
AuthorVelka Gverić-Krečak
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Despite being extremely rare, Guillain-Barré syndrome (GBS) has been recognized as a neurological complication of multiple myeloma, with variable responses to plasmapheresis (PEX), intravenous immunoglobulins (IVIG), and anti-myeloma therapies. In this paper, we report a case of a female patient with asymptomatic multiple myeloma (aMM) who initially presented as PEX- and IVIG-refractory GBS. After failure of PEX, IVIG, and anti-myeloma therapy (bortezomib, melphalan, and prednisone), the patient was eventually successfully treated with low-dose rituximab (100 mg/m2 per week in four doses). To the best of our knowledge, this is the first case to report successful treatment of refractory GBS potentially associated to aMM with low-dose rituximab. Additional studies are needed to elucidate the pathophysiological processes and the interplay between the dysregulated immune response, monoclonal immunoglobulin (MG), and neural tissue damage in GBS patients. Also, the potential role of rituximab in the treatment of MG-associated GBS warrants further exploration.
Abstract (croatian)
Guillain-Barréov sindrom (GBS) iznimno rijetko komplicira multipli mijelom. Način liječenja ove neurološke komplikacije u kontekstu multiplog mijeloma nije definiran s obzirom na to da plazmafereza, intravenski imunoglobulini i (imuno) kemoterapije usmjereni na plazmastanični klon polučuju vrlo varijabilne kliničke odgovore. U ovom radu prikazujemo klinički tijek bolesnice s asimptomatskim multiplim mijelomom (aMM) koja se pri dijagnozi prezentirala kao refraktorni GBS. Nakon neuspješnog liječenja plazmaferezom, imunoglobulinima i kemoterapijom (bortezomib, melfalan i prednizon) bolesnicu smo uspješno liječili niskim dozama rituksimaba (100 mg/m2 na tjedan u četiri doze). Koliko nam je poznato, ovo je prvi slučaj u kojem je refraktorni GBS potencijalno povezan s aMM uspješno liječen niskim dozama rituksimaba. Dodatne studije su potrebne kako bi razjasnile patofiziološke procese između monoklonskog imunoglobulina (MG) i oštećenja perifernog živčanog sustava u bolesnika s GBS. Također, uloga rituksimaba u liječenju bolesnika s GBS povezanim s MG zaslužuje dodatna istraživanja.
Keywords (english)
Keywords (croatian)
Languageenglish
Languagecroatian
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleActa clinica Croatica
Numberingvol. 62, no. 2, pp. 382-385
p-ISSN0353-9466
e-ISSN1333-9451
DOIhttps://doi.org/10.20471/acc.2023.62.02.19
URN:NBNurn:nbn:hr:184:287378
Publication2023
Document URLhttps://hrcak.srce.hr/308847
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2023-10-20 10:06:33